MDS Proteomics, Chugai Pharmaceutical, SurroMed, Amersham, Beckman Coulter | GenomeWeb

MDS Proteomics Reports Third Quarter 2002 Earnings; Hopes for Partner by Year’s End

In MDS’ third quarter 2002 fiscal year earnings report, released September 19, MDS Proteomics’ revenue and burn rate remained unchanged from the comparable period a year ago. In both periods, MDSP earned $1 million Canadian ($630,000) in revenue, and spent $12 million Canadian ($7.6 million). The impact on MDS’ earnings due MDSP’s cash burn increased from six cents a share from 5 cents a share a year ago.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.